Clinical Trial Update: Non-small Cell Lung Cancer Registry [Phase 4]

View source ↗

Summary

A completed Phase 4 registry update for non-small cell lung cancer focusing on malignant pleural effusion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Pleural Effusion
• Non-small Cell Lung Cancer

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Non-Small-Cell Lung Cancer, Pleural Effusion, Malignant | Phase 4 | Status: COMPLETED